Analyst firms · Morgan Stanley · BPMC
Morgan Stanley BPMC price target and rating history
Blueprint Medicines Corporation (BPMC) · Health Care
Morgan Stanley rates Blueprint Medicines Corporation (BPMC) Equal-Weight with a $100 price target, as of its latest action on Mar 20, 2025. It has published 5 rating actions on BPMC since July 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $100
- Median target, all firms
- Too few
- Actions on BPMC
- 5
Morgan Stanley price target on BPMC
Every Morgan Stanley rating on BPMC
- Mar 20, 2025
- Feb 1, 2022
- Nov 19, 2021
- Oct 29, 2021
- Jul 30, 2021
Questions about Morgan Stanley and BPMC
- What is Morgan Stanley's price target for BPMC?
- Morgan Stanley's latest stated price target for Blueprint Medicines Corporation (BPMC) is $100, from its action on Mar 20, 2025.
- What is Morgan Stanley's rating on BPMC?
- Morgan Stanley rates BPMC Equal-Weight, a neutral rating, as of Mar 20, 2025.
- When did Morgan Stanley last change its view on BPMC?
- On Mar 20, 2025, Morgan Stanley resumes coverage at Equal-Weight, price target $100.
More BPMC rating histories
All Morgan Stanley ratingsBPMC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.